title: Expression of the Cdx1 and Cdx2 homeotic genes leads to reduced malignancy in colon cancer-derived cells.
abstract: We have previously described an inverse relationship between Cdx1 and Cdx2 mRNA levels and the extent of dysplasia and severity of clinical outcome in colorectal carcinoma, suggesting that altered expression of these genes was associated with colorectal carcinogenesis or tumor progression. To investigate further their involvement in the physiopathology of colorectal cancer, HT29 colon carcinoma cells that show very low Cdx expression were transfected with Cdx1 and/or Cdx2 cDNA to elicit their overexpression. Growth rate, tumorigenicity, resistance to apoptosis, and migration potential of the corresponding cells were analyzed. Growth rate of cells overexpressing Cdx2 decreased by half, whereas overexpression of Cdx1 had no effect. However, cells overexpressing both Cdxs had a growth rate reduced to 20% of control. In cells overexpressing Cdx1 or Cdx2, tumorigenicity and resistance to apoptosis induced by serum starvation, ceramide, or staurosporine were not changed compared with control cells; yet phorbol ester-stimulated cell migration was decreased by 50%. In cells overexpressing both Cdx1 and Cdx2, tumorigenicity was decreased by 50%, resistance to apoptosis was significantly lowered, and stimulated cell migration was further decreased to 15% of control compared with cells expressing Cdx1 or Cdx2. Finally, cells overexpressing both Cdxs showed strongly decreased Bcl-2 expression, which could account for their increased sensitivity to apoptosis. These findings show that, in HT29 cells, both Cdx1 and Cdx2 genes must be expressed to reduce tumorigenic potential, to increase sensitivity to apoptosis, and to reduce cell migration, suggesting that the two genes control the normal phenotype by independent pathways. This may explain why loss of Cdx1 or Cdx2 expression is associated with tumor development and invasiveness in colorectal tumors.
authors.affiliation: U.315 INSERM, F 13009 Marseille, France.
authors.forename: G V
authors.initials: GV
authors.lastname: Mallo
authors.forename: P
authors.initials: P
authors.lastname: Soubeyran
authors.forename: J C
authors.initials: JC
authors.lastname: Lissitzky
authors.forename: F
authors.initials: F
authors.lastname: André
authors.forename: C
authors.initials: C
authors.lastname: Farnarier
authors.forename: J
authors.initials: J
authors.lastname: Marvaldi
authors.forename: J C
authors.initials: JC
authors.lastname: Dagorn
authors.forename: J L
authors.initials: JL
authors.lastname: Iovanna
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D030161:Avian Proteins; D001483:Base Sequence; D000071616:CDX2 Transcription Factor; D002455:Cell Division; D002465:Cell Movement / Q000187:drug effects; D002518:Ceramides / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000235:genetics* / Q000473:pathology; D016895:Culture Media, Serum-Free; D017931:DNA Primers; D015536:Down-Regulation; D005801:Genes, Homeobox; D019254:Genes, bcl-2; D019073:HT29 Cells; D018398:Homeodomain Proteins / Q000235:genetics*; D006801:Humans; D019311:Staurosporine / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015534:Trans-Activators; D014162:Transfection
chemical_list: D030161:Avian Proteins; C491273:CDX1 protein, human; D000071616:CDX2 Transcription Factor; C491270:CDX2 protein, human; D002518:Ceramides; D016895:Culture Media, Serum-Free; D017931:DNA Primers; D018398:Homeodomain Proteins; D015534:Trans-Activators; D019311:Staurosporine; D013755:Tetradecanoylphorbol Acetate